What is the appropriate insulin regimen, including type, dose, and timing, for a pregnant woman?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

How to Give Insulin for Pregnant Women

Insulin is the preferred first-line pharmacologic agent for managing all types of diabetes in pregnancy (type 1, type 2, and gestational diabetes), and should be administered using a physiologic basal-bolus regimen with frequent titration based on continuous or frequent glucose monitoring. 1, 2

Insulin Regimen Structure

For Type 1 Diabetes in Pregnancy

Use automated insulin delivery (AID) systems or intensive basal-bolus regimens as first-line therapy. 1, 2

  • AID systems (hybrid closed-loop pumps) are suggested over standard insulin pumps or multiple daily injections when available 2

    • Set pump glucose target to 100 mg/dL 1
    • Provides superior nocturnal time-in-range (6.58% higher) and reduced hypoglycemia (1.86% lower nocturnal time-below-range) compared to standard care 1
    • Not all AID algorithms are appropriate for pregnancy—choose systems that can achieve pregnancy-specific fasting and postprandial targets 2

  • If using multiple daily injections: Administer 3 doses of rapid-acting insulin before meals plus intermediate-acting insulin at bedtime (4 times daily regimen) 3

For Type 2 Diabetes and Gestational Diabetes

Initiate insulin when nutritional and lifestyle modifications fail to achieve glucose targets. 1, 4

  • Start with a 4 times daily regimen: rapid-acting insulin before each meal plus intermediate-acting insulin at bedtime 3

    • This regimen achieves better glycemic control than twice-daily dosing (mean blood glucose decreased by 0.19-0.44 mmol/L) 3
    • Results in 59% lower overall neonatal morbidity compared to twice-daily regimens 3
    • Reduces neonatal hypoglycemia risk by 83-88% 3

  • Alternative for less complex cases: Combined regular and intermediate insulin twice daily (morning and evening) may be considered, though less optimal 3

Glucose Monitoring Targets

Use pregnancy-specific glucose targets, NOT standard diabetes targets:

  • Fasting: <95 mg/dL (5.3 mmol/L)
  • 1-hour postprandial: <140 mg/dL (7.8 mmol/L)
  • 2-hour postprandial: <120 mg/dL (6.7 mmol/L) 2

For CGM users: Target time-in-range of 63-140 mg/dL, but adjust insulin based on fasting and postprandial values, not a single target 2

Insulin Dosing Across Pregnancy

Dose Progression by Trimester

Insulin requirements increase dramatically as pregnancy progresses, requiring frequent titration:

  • First trimester: Lower baseline requirements
  • Second/third trimester: Progressive increase, peaking at approximately 1.0 units/kg in late pregnancy 5, 6
  • Percentage of preprandial (bolus) insulin increases from ~54% in first trimester to 64-67% in second/third trimester for preexisting diabetes 6
  • Late third trimester: Requirements may plateau; a rapid decrease may indicate placental insufficiency 1

Postpartum Dose Reduction

Immediately reduce total insulin dose by 50% after delivery to prevent severe hypoglycemia 5

  • Type 1 diabetes: Continue insulin postpartum with reduced doses (26.9% average decrease) 6
  • Type 2 diabetes: 18.6% still require insulin postpartum (36.7% average dose decrease) 6
  • Gestational diabetes: Discontinue insulin completely postpartum 6

Intrapartum Management

Continue subcutaneous insulin during labor and delivery rather than switching to intravenous insulin. 5, 7

  • Target glucose during active labor: 4.0-7.0 mmol/L (72-126 mg/dL) 7
  • Provide intravenous glucose infusion at 3 g/hour during active labor 7
  • For pump users: Continue basal insulin via pump 7
  • For multiple daily injection users: Discontinue routine injections during active labor, give supplemental rapid-acting insulin only if glucose exceeds target 7
  • This approach achieves mean glucose of 5.9-7.1 mmol/L during labor with only 6-11% maternal hypoglycemia 7

Technology Considerations

Continuous Glucose Monitoring

Use CGM for all pregnant women with type 1 diabetes; consider for type 2 diabetes. 2

  • CGM improves glycemic metrics and neonatal outcomes in type 1 diabetes pregnancy 5
  • For type 2 diabetes, both CGM and self-monitoring blood glucose are reasonable alternatives 2

Critical Safety Points

  • Monitor for ketones regularly when using pumps or AID systems 5
  • Have explicit protocols for pump failure 5
  • Adjust active insulin time settings to meet strict pregnancy targets (often requires "off-label" strategies) 5
  • Educate patients on euglycemic diabetic ketoacidosis prevention 5

Common Pitfalls to Avoid

  • Do not use a single CGM target (e.g., <140 mg/dL) for insulin adjustment—use distinct fasting and postprandial targets 2
  • Do not continue pre-pregnancy insulin doses postpartum—this causes severe hypoglycemia 5
  • Do not use twice-daily insulin regimens when four-times-daily is feasible—outcomes are significantly worse 3
  • Do not assume metformin is equivalent to insulin—metformin has 14-46% monotherapy failure rates and crosses the placenta 1

References

Related Questions

In a 32‑week pregnant woman weighing 77 kg with overt (pre‑gestational) diabetes, what basal and bolus insulin doses should be prescribed?
How should the insulins mentioned (e.g., insulin aspart ভাই insulin lispro, insulin detemir, insulin glargine, NPH) be administered in a pregnant woman?
For a 25‑year‑old woman at 28 weeks gestation with type 2 diabetes, weight 114 kg, on insulin glargine (Lantus) 32 U daily, insulin‑to‑carbohydrate ratio 1 U:5 g, and insulin sensitivity factor 1 U:25 mg/dL, who ate 55 g carbohydrate at 6 pm and had blood glucose 183 mg/dL at 9 pm and fasting glucose 187 mg/dL, how should her insulin sensitivity factor, insulin‑to‑carbohydrate ratio, and basal insulin dose be adjusted?
A 28‑week pregnant woman with type 2 diabetes mellitus, weight 114 lb (≈52 kg) and A1c 6.7%, what should her insulin glargine (Lantus) dose, insulin sensitivity factor (ISF), and insulin‑to‑carbohydrate ratio (ICR) be?
What is the preferred long‑acting basal insulin for a pregnant woman with diabetes?
In a 72‑year‑old obese woman (BMI 34.2) with hypertension, prior coronary artery disease (surgery 1983), a provoked upper‑extremity deep vein thrombosis, mild chronic kidney disease (eGFR ≈ 90 mL/min), and on low‑dose aspirin, what is the peri‑operative cardiac risk for a short‑duration hysteroscopic procedure and what thromboprophylaxis regimen is recommended?
What is the recommended dosage of tobramycin for adults and children, including adjustments for severe infections, cystic fibrosis, and renal impairment?
What dose and frequency of vitamin B12 should be given to a patient with vitamin B12 deficiency, an elevated homocysteine level of 18 µmol/L, and a recent cerebrovascular accident?
For a patient receiving neoadjuvant platinum‑based chemotherapy before radical cystectomy, how many cycles should be given, and what are the expected objective response rate and median overall survival?
What is the appropriate evaluation and treatment for a patient presenting with a resting heart rate >100 bpm?
Is empirical resmetirom appropriate for patients with fatty liver and elevated SGPT (serum glutamate pyruvate transaminase) when elastography is not available?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.